Indian pharma industry may rebound to 8-11 pc growth rate; inflationary pressures, regulatory norms key risks: Alkem

On the outlook for the domestic business, Alkem Laboratories said, "With easing out of COVID-19 restrictions, resumption of travel, normalisation of supply chain and manufacturing activities, reopening of schools and offices, and a resumption of deferred elective medical treatments, the Indian pharmaceutical industry is expected to rebound to a normalised growth rate of 8-11 per cent."

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/xdHlmhe
via IFTTT